Comparison
DSIP vs. Melanotan II
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
62568-57-4
121062-08-6
Molecular weight
848.81 g/mol
1024.18 g/mol
Half-life
0.1 h
1 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Mechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
5
of which in humans
1
5
Effects recorded
3
4
Open conflicts
1
0
Documented adverse events
1
3